Healthcare provider profile · identity verified

Srinivas Jonnala, MD

Allopathic & Osteopathic Physicians|Internal Medicine · ROCHESTER, NY · NPI 1629007836

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Srinivas Jonnala, MD received $244.40 in general payments during 2025 across 2 reported records.

AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$244.40

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$244.40	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$244.40	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$122.88	1	2025
Source payment records 2025-09-09 · AstraZeneca Pharmaceuticals LP · $122.88 · Open Payments source
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$121.52	1	2025
Source payment records 2025-10-29 · AstraZeneca Pharmaceuticals LP · $121.52 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	984	334
Lisinopril	Lisinopril	792	243
Levothyroxine Sodium	Levothyroxine Sodium	694	197
Amlodipine Besylate	Amlodipine Besylate	681	221
Losartan Potassium	Losartan Potassium	472	150
Gabapentin	Gabapentin	428	116
Simvastatin	Simvastatin	426	127
Metoprolol Succinate	Metoprolol Succinate	371	129
Omeprazole	Omeprazole	364	119
Metformin Hcl	Metformin Hcl	341	113
Pantoprazole Sodium	Pantoprazole Sodium	336	106
Hydrochlorothiazide	Hydrochlorothiazide	328	103
Rosuvastatin Calcium	Rosuvastatin Calcium	313	101
Metoprolol Tartrate	Metoprolol Tartrate	280	90
Allopurinol	Allopurinol	222	68
Tamsulosin Hcl	Tamsulosin Hcl	215	65
Famotidine	Famotidine	214	65
Trazodone Hcl	Trazodone Hcl	199	52
Albuterol Sulfate Hfa	Albuterol Sulfate	195	69
Eliquis	Apixaban	167	44
Duloxetine Hcl	Duloxetine Hcl	162	44
Atenolol	Atenolol	154	51
Sertraline Hcl	Sertraline Hcl	151	51
Furosemide	Furosemide	148	49
Alprazolam	Alprazolam	141	29
Fluticasone Propionate	Fluticasone Propionate	124	52
Meloxicam	Meloxicam	124	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	120	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	120	37
Lovastatin	Lovastatin	119	47
Metformin Hcl Er	Metformin Hcl	113	42
Clopidogrel	Clopidogrel Bisulfate	111	35
Tramadol Hcl	Tramadol Hcl	110	22
Venlafaxine Hcl Er	Venlafaxine Hcl	107	23
Buspirone Hcl	Buspirone Hcl	106	25
Paroxetine Hcl	Paroxetine Hcl	105	30
Glimepiride	Glimepiride	100	32
Zolpidem Tartrate	Zolpidem Tartrate	98	19
Fluoxetine Hcl	Fluoxetine Hcl	92	24
Pregabalin	Pregabalin	91	18
Montelukast Sodium	Montelukast Sodium	88	26
Pravastatin Sodium	Pravastatin Sodium	87	30
Citalopram Hbr	Citalopram Hydrobromide	85	27
Escitalopram Oxalate	Escitalopram Oxalate	79	19
Lorazepam	Lorazepam	78	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	76	26
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	75	22
Warfarin Sodium	Warfarin Sodium	75	19
Spironolactone	Spironolactone	72	29
Finasteride	Finasteride	71	23
Torsemide	Torsemide	70	23
Carvedilol	Carvedilol	69	22
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	66	19
Bupropion Xl	Bupropion Hcl	65	18
Glipizide	Glipizide	61	23
Ozempic	Semaglutide	61	15
Felodipine Er	Felodipine	60	11
Prednisone	Prednisone	59	45
Fenofibrate	Fenofibrate Nanocrystallized	56	18
Ibuprofen	Ibuprofen	54	17
Irbesartan	Irbesartan	54	16
Oxybutynin Chloride Er	Oxybutynin Chloride	53	12
Januvia	Sitagliptin Phosphate	51	12
Insulin Lispro Kwikpen U-100	Insulin Lispro	49	14
Glipizide Er	Glipizide	48	14
Potassium Chloride	Potassium Chloride	48	16
Hydralazine Hcl	Hydralazine Hcl	47	11
Hydroxyzine Hcl	Hydroxyzine Hcl	46	20
Meclizine Hcl	Meclizine Hcl	45	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	44	suppressed
Amoxicillin	Amoxicillin	43	29
Diazepam	Diazepam	43	suppressed
Risperidone	Risperidone	41	suppressed
Celecoxib	Celecoxib	40	15
Baclofen	Baclofen	39	suppressed
Ezetimibe	Ezetimibe	39	15
Triamcinolone Acetonide	Triamcinolone Acetonide	39	23
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	38	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	37	11
Mirtazapine	Mirtazapine	37	14
Alendronate Sodium	Alendronate Sodium	36	14
Dicyclomine Hcl	Dicyclomine Hcl	36	11
Eszopiclone	Eszopiclone	36	suppressed
Clonazepam	Clonazepam	35	suppressed
Synthroid	Levothyroxine Sodium	35	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	suppressed
Chlorthalidone	Chlorthalidone	33	suppressed
Ramipril	Ramipril	33	suppressed
Jardiance	Empagliflozin	32	12
Labetalol Hcl	Labetalol Hcl	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	12
Trulicity	Dulaglutide	31	suppressed
Lansoprazole	Lansoprazole	30	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	29	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	suppressed
Xarelto	Rivaroxaban	29	11
Lactulose	Lactulose	28	suppressed
Mometasone Furoate	Mometasone Furoate	28	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	28	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	11
Ketoconazole	Ketoconazole	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Entresto	Sacubitril/Valsartan	25	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Nystatin	Nystatin	23	13
Ibandronate Sodium	Ibandronate Sodium	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	16
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	22	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Midodrine Hcl	Midodrine Hcl	21	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Valsartan	Valsartan	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Hydrocortisone	Hydrocortisone	19	13
Myrbetriq	Mirabegron	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Varenicline Tartrate	Varenicline Tartrate	19	suppressed
Cephalexin	Cephalexin	18	14
Combivent Respimat	Ipratropium/Albuterol Sulfate	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Unifine Pentips Plus	Pen Needle, Diabetic	18	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	suppressed
Loperamide	Loperamide Hcl	17	suppressed
Methimazole	Methimazole	17	suppressed
Pen Needle	Pen Needle, Diabetic	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Carbamazepine	Carbamazepine	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	16
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	15	suppressed
Digoxin	Digoxin	15	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Temazepam	Temazepam	15	suppressed
Wegovy	Semaglutide	15	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Topiramate	Topiramate	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Zolpidem Tartrate Er	Zolpidem Tartrate	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Nadolol	Nadolol	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$244.40 · 2 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA, BREZTRI	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error